Core Viewpoint - The executive order signed by Trump aims to lower prescription drug prices in the U.S. by requiring pharmaceutical companies to match the lowest prices in comparable developed countries, but the short-term impact on the industry is expected to be limited [1] Group 1: Executive Order Details - The executive order titled "Most Favored Nation Pricing for Prescription Drugs" was signed on May 12, 2025 [1] - It mandates that drug prices in the U.S. should align with the lowest prices in comparable developed nations [1] - The order also proposes to increase price transparency in the U.S. drug market and reduce the profit margins of middlemen, such as Pharmacy Benefit Managers (PBMs) [1] Group 2: Industry Impact - The implementation of the executive order is anticipated to face significant challenges, leading to a limited short-term impact on the pharmaceutical industry [1]

Core Viewpoint - The U.S. government aims to significantly reduce prescription drug costs and ensure fairness for American citizens by eliminating intermediaries and promoting direct sales at the lowest prices available [1] Group 1 - The initiative will lead to a decrease in drug prices for American citizens [1] - The strategy involves removing middlemen in the pharmaceutical supply chain [1] - The government plans to implement a system that allows drugs to be sold at the most favored nation prices directly to consumers [1]